The Proteasome Inhibitor Carfilzomib Suppresses Parathyroid Hormone-induced Osteoclastogenesis through a RANKL-mediated Signaling Pathway

HDAC4 integrates PTH and sympathetic signaling in osteoblasts

(2014) Arnaud Obri et al.   JOURNAL OF CELL BIOLOGY

A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity

(2014) H Eda et al.   LEUKEMIA

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

(2014) J R Berenson et al.   LEUKEMIA

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma

(2013) Bo Hu et al.   PLoS One

NHERF1 regulation of PTH-dependent bimodal Pi transport in osteoblasts

(2012) Bin Wang et al.   BONE

Severe hypercalcemia due to teriparatide

(2012) Cumali Karatoprak et al.   INDIAN JOURNAL OF PHARMACOLOGY

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

(2012) M A Hurchla et al.   LEUKEMIA

Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4

(2011) Johannes Backs et al.   JOURNAL OF CELL BIOLOGY

Parathyroid Hormone Receptor Directly Interacts with Dishevelled to Regulate β-Catenin Signaling and Osteoclastogenesis

(2010) Guillermo Romero et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Smurf1 inhibits mesenchymal stem cell proliferation and differentiation into osteoblasts through JunB degradation

(2010) Lan Zhao et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Ubiquitin-dependent degradation of HDAC4, a new regulator of random cell motility

(2010) Nadia Cernotta et al.   MOLECULAR BIOLOGY OF THE CELL

Characterization of Wnt/β-catenin signalling in osteoclasts in multiple myeloma

(2009) Ya-Wei Qiang et al.   BRITISH JOURNAL OF HAEMATOLOGY

PTH and PTHrP signaling in osteoblasts

(2009) Nabanita S. Datta et al.   CELLULAR SIGNALLING

Proteasome inhibitors impair RANKL-induced NF-κB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IκBα signaling cascades

(2009) Estabelle Ang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

(2008) Angela Pennisi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions

(2008) P. Boissy et al.   LEUKEMIA RESEARCH